District Court Rules DNA Analysis Claims Reciting Mathematical Algorithms Ineligible Under § 101

Oct 26, 2020

Reading Time : 3 min

The Cybergenetics patents at issue—U.S. Patent Nos. 8,898,021 and 9,708,642—describe a variation of a traditional method of identifying an individual based on a DNA sample. The traditional method uses “PCR (polymerase chain reaction) amplification” to transform the DNA sample into data that are unique to an individual and thus can be used to identify that individual. The method is not useful, however, when the sample contains DNA from multiple sources because the transformed data are “mixed” and do not correspond to one individual.

The patents address that problem by employing what they call “deconvolution”—a process that accounts for multiple individuals in a DNA sample by “calculating the variance of the DNA data produced by PCR amplification and accounting for that variance in subsequent probability calculations.” The probability calculations “predict the identity of an individual in the sample and calculate the likelihood that the prediction is correct.” In other words, the patented methods determine the likelihood that a given individual’s DNA is contained in a sample instead of merely identifying one individual.

Cybergenetics asserted several claims of these patents against the Institute of Environmental Science and Research, and NicheVision Inc., based on their alleged use of “deconvolution” technology. The court granted the defendants’ motion to dismiss after determining that the asserted claims fail both steps of the Alice framework.

Under step one, the court explained that the Cybergenetics claims “recite mathematical algorithms to produce a numerical output as the entirety of the method.” In particular, the claimed “deconvolution” process “describes the process of calculating a variance (a numerical result) and then accounting for that variance in subsequent statistical calculations (also numerical results).” The court further explained that the U.S. Supreme Court and Federal Circuit have repeatedly held that mathematical algorithms are examples of abstract ideas. It then found that the use of algorithms is “⁠[t]he only difference between” conventional methods and the claimed methods, further showing that the claims are “directed to” such abstract ideas.

The court rejected Cybergenetics’ argument that the asserted claims were akin to those analyzed in the Federal Circuit’s Thales, McRO and CardioNet cases in which claims survived Alice challenges despite reciting mathematical algorithms. The court explained that the mathematical algorithms in those cases “were used as part of a non-mathematical process” (emphasis added). For example, in Thales, a mathematical algorithm and its result were used “to track the position and orientation of [an] object.” In McRO, an algorithm was used to “generate a tangible product, namely a video of a 3-D character speaking [] recorded audio.” And in CardioNet, the claims improved the operation of a cardiac monitoring machine, albeit through the use of an algorithm. Unlike in those cases, “the numerical result” in the Cybergenetics claims is the claimed “improvement,” and the numerical result is not used for any “non-mathematical process.”

Under step two, the court explained that the Cybergenetics claims fail to recite an “inventive concept” because they do not recite any “elements other than the computation of mathematical algorithms and reporting the numerical results.” Specifically, some claims merely recite mathematical algorithms, some recite a generic computer that calculates the mathematical algorithms (or merely display the results of such calculations) and some recite the conventional step of using “PCR amplification” to transform a DNA sample into data. According to the court, all three categories of claims “capture patent-ineligible ideas.” 

The court rejected the argument that the “inventive concept” is a specific application of a mathematical technique to “computer-based DNA analysis” or to “probabilistic genotyping.” As the court explained, “[c]ourts have consistently rejected finding a claim provides an inventive concept simply because it is limited ‘to one field of use.’”

Practice Tip: After six years, courts continue to use Alice to dismiss patent claims directed to so-called “abstract ideas.” The Cybergenetics case demonstrates the fine line between claims that are directed to a mathematical algorithm—one of the few things the higher courts have specifically identified as an “abstract idea”—and claims that merely use them. When possible, patentees should draft claims (and specifications) in a way that emphasizes tangible improvements even when achieving such improvements requires using a mathematical algorithm. By the same token, defendants should consider attacking any patent claims that rely on a mathematical algorithm, and they should try to characterize that algorithm as the focus of the patent and the claims. The Cybergenetics case will certainly be one worth monitoring on appeal (if there is one) to see if the Federal Circuit agrees with the district court’s analysis.

Cybergenetics Corp. v. Institute of Environmental Science and Research, 5:19-cv-1197 (N.D. Ohio Sep. 29, 2020) (Lioi, J.)

Share This Insight

Previous Entries

IP Newsflash

October 1, 2025

In a recent final written decision, the PTAB determined that a reference patent was not prior art, despite the petitioner’s post‑filing attempt to correct its petition. While the petitioner argued that it intended to rely on the patent application’s earlier date of publication, both the corrected petition and the expert declaration continued to reference the issued patent rather than the published application.

...

Read More

IP Newsflash

September 30, 2025

The USPTO Director recently granted a petitioner’s request for rehearing of the decision discretionarily denying institution of inter partes review, ultimately vacating the original decision, and referring the petition to the board for an institution decision.

...

Read More

IP Newsflash

September 25, 2025

In considering claims to a method of reducing cardiovascular events, the Federal Circuit held that the term a “clinically proven effective” amount did not render the claims patentable over the prior art. Specifically, the Federal Circuit held that the “clinically proven effective” amount, whether limiting or not, could not be used to distinguish the prior art because the claims also specified the exact amount of the drugs to be administered in the method. The Federal Circuit also rejected patentee’s evidence of unexpected results because that evidence was tied solely to the “clinically proven effective” limitation.

...

Read More

IP Newsflash

September 24, 2025

The Federal Circuit reversed a district court’s denial of judgment as a matter of law on non-infringement, thereby setting aside a $106 million jury verdict, after holding that prosecution history estoppel barred the patentee from asserting infringement under the doctrine of equivalents.

...

Read More

IP Newsflash

September 17, 2025

A magistrate judge in the District of Delaware issued a Report and Recommendation, that found the sole asserted claim was a “single means” claim and therefore invalid for lack of enablement. In reaching that conclusion, the magistrate judge rejected the patentee’s argument that the preamble of the claim disclosed a second element that satisfied the combination requirement of Section 112, paragraph 6 because the preamble simply recited a descriptor of the very apparatus that was the subject of the means-plus-function limitation in the body of the claim. The district court judge presiding over this case has scheduled a hearing to review the magistrate’s ruling.

...

Read More

IP Newsflash

September 9, 2025

The Federal Circuit has affirmed the PTAB’s determination that a patent challenger did not show the challenged claims were unpatentable for obviousness. The Federal Circuit concluded that substantial evidence, which included expert testimony, showed there was no motivation to combine the references.

...

Read More

IP Newsflash

August 29, 2025

In a recent order addressing four IPR proceedings, the PTAB exercised its inherent authority under 37 C.F.R. § 42.5(a) to sua sponte authorize post-hearing discovery on a potentially dispositive privity issue. The order followed a Director review decision that vacated and remanded earlier IPRs involving the same parties, patent family, and privity issue. 

...

Read More

IP Newsflash

August 29, 2025

The Patent Trial and Appeal Board denied institution of an inter partes review petition in part because it determined that a patent reference was not prior art under the common ownership exception of pre-AIA 35 U.S.C. § 103(c)(1).

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.